
Dr. Reddy’s Laboratories Limited (REDY) – Earnings growth seems attractive for investors
in Company Report , Healthcare & Life Sciences , Pharma & Biotech on August 31, 2022This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.
Dr. Reddy’s Laboratories Limited (REDY)
Dr. Reddy is one of the leading pharmaceutical company in Indian sub-continent, and is expanding to other parts of the world. One of the challenge being faced in global expansion is the supply chain disruptions.
Highlights
Valuation
– Enterprise Value
– CrispIdea Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum
Actual & Historical Performance
– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– M&A Deals
Peer Performance
– Summary
– Profitability
– Growth
– Price Performance
Ownership
Stock Price Performance
Crispidea Coverage
No of Pages : 33